N1-methylnicotinamide (mNAM) is a products of the S-adenosylmethionine-dependent enzyme, N-methyltransferase (NNMT); nicotinamide (NAM) is the substrate of this reaction. In addition to being a vitamin B3 catabolites, it has been assigned a role as a vasoprotective, anti-inflammatory and anti-thrombotic agent. High circulating levels of mNAM have been reported in patients with cardiovascular disease and some types of cancer, and has been related to obesity and insulin resistance (2). mNAM seems to be a signalling molecule, but whether this metabolite mediates beneficial and protective effects or play a role in pathogenesis of various diseases is currently under investigation (3).
N1-methylnicotinamide in plasma/serum/urine is a potential marker of vitamin B3 status.
Matrix: Serum, EDTA plasma and urine
Volume: Minimum volume is 60 µL, but 200 µL is optimal and allows reanalysis.
Preparation and stability: NA.
Reported values: 20-250 nmol/l.
Intraclass correlation coefficient (ICC): na.
1. Midttun, O., Hustad, S., and Ueland, P.M. (2009). Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Sp 23, 1371-79.
2. Pissios, P. (2017). Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends Endocrinol Metab, 28, 340-353.
3. Hwang, E. S., & Song, S. B. (2020). Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment. Biomolecules, 10, 687.